Cargando…

Targeting lung cancer initiating cells by all-trans retinoic acid-loaded lipid-PLGA nanoparticles with CD133 aptamers

Lung cancer initiating cells represent a specific subpopulation of lung cancer cells, which significantly contribute to the initiation, metastasis and recurrence of lung cancer. CD133, initially considered a marker of stem cells, is now considered as a marker for lung cancer initiating cells. All-tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yu, Zhao, Juan, Sun, Jing, Huang, Lu, Li, Qingfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257334/
https://www.ncbi.nlm.nih.gov/pubmed/30542415
http://dx.doi.org/10.3892/etm.2018.6762
_version_ 1783374302558552064
author Zhang, Yu
Zhao, Juan
Sun, Jing
Huang, Lu
Li, Qingfeng
author_facet Zhang, Yu
Zhao, Juan
Sun, Jing
Huang, Lu
Li, Qingfeng
author_sort Zhang, Yu
collection PubMed
description Lung cancer initiating cells represent a specific subpopulation of lung cancer cells, which significantly contribute to the initiation, metastasis and recurrence of lung cancer. CD133, initially considered a marker of stem cells, is now considered as a marker for lung cancer initiating cells. All-trans retinoic acid (RA) has been demonstrated to cause the differentiation, inhibition of proliferation, and apoptosis of cancer cells and cancer initiating cells. However, there have been no reports on the activity of RA against lung cancer initiating cells. In the present study, the activity of RA against lung cancer initiating cells was investigated by determining the cytotoxicity, and performing a tumorsphere assay and flow cytometry-based analysis. In addition, to promote the therapeutic effect of RA in CD133(+) lung cancer initiating cells, RA-loaded lipid poly(lactic-co-glycolic acid) (PLGA) nanoparticles with CD133 aptamers (RA-LPNPs-CD133) were developed. The activity of RA and RA-LPNPs-CD133 against lung cancer initiating cells was also investigated. RA-LPNPs-CD133 had a size of 129.9 nm, and exhibited sustained release of RA during the 144-h period. For the first time, to the best of our knowledge, the present study demonstrated that RA exerted potent activity towards CD133(+) lung cancer initiating cells. The results also showed that RA-LPNPs-CD133 efficiently and specifically promoted the delivery of RA to CD133(+) lung cancer initiating cells, exhibiting superior inhibitory effects against CD133(+) lung cancer initiating cells compared with non-targeted nanoparticles and RA. To the best of our knowledge, the present study is the first to report the promotion of RA delivery via nanoparticles to lung cancer initiating cells and achievement of a superior inhibitory effect against lung cancer initiating cells by the utilization of CD133 aptamers. Therefore, RA-LPNPs-CD133 represents a promising tool for the elimination of lung cancer initiating cells.
format Online
Article
Text
id pubmed-6257334
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-62573342018-12-12 Targeting lung cancer initiating cells by all-trans retinoic acid-loaded lipid-PLGA nanoparticles with CD133 aptamers Zhang, Yu Zhao, Juan Sun, Jing Huang, Lu Li, Qingfeng Exp Ther Med Articles Lung cancer initiating cells represent a specific subpopulation of lung cancer cells, which significantly contribute to the initiation, metastasis and recurrence of lung cancer. CD133, initially considered a marker of stem cells, is now considered as a marker for lung cancer initiating cells. All-trans retinoic acid (RA) has been demonstrated to cause the differentiation, inhibition of proliferation, and apoptosis of cancer cells and cancer initiating cells. However, there have been no reports on the activity of RA against lung cancer initiating cells. In the present study, the activity of RA against lung cancer initiating cells was investigated by determining the cytotoxicity, and performing a tumorsphere assay and flow cytometry-based analysis. In addition, to promote the therapeutic effect of RA in CD133(+) lung cancer initiating cells, RA-loaded lipid poly(lactic-co-glycolic acid) (PLGA) nanoparticles with CD133 aptamers (RA-LPNPs-CD133) were developed. The activity of RA and RA-LPNPs-CD133 against lung cancer initiating cells was also investigated. RA-LPNPs-CD133 had a size of 129.9 nm, and exhibited sustained release of RA during the 144-h period. For the first time, to the best of our knowledge, the present study demonstrated that RA exerted potent activity towards CD133(+) lung cancer initiating cells. The results also showed that RA-LPNPs-CD133 efficiently and specifically promoted the delivery of RA to CD133(+) lung cancer initiating cells, exhibiting superior inhibitory effects against CD133(+) lung cancer initiating cells compared with non-targeted nanoparticles and RA. To the best of our knowledge, the present study is the first to report the promotion of RA delivery via nanoparticles to lung cancer initiating cells and achievement of a superior inhibitory effect against lung cancer initiating cells by the utilization of CD133 aptamers. Therefore, RA-LPNPs-CD133 represents a promising tool for the elimination of lung cancer initiating cells. D.A. Spandidos 2018-12 2018-09-19 /pmc/articles/PMC6257334/ /pubmed/30542415 http://dx.doi.org/10.3892/etm.2018.6762 Text en Copyright: © Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Zhang, Yu
Zhao, Juan
Sun, Jing
Huang, Lu
Li, Qingfeng
Targeting lung cancer initiating cells by all-trans retinoic acid-loaded lipid-PLGA nanoparticles with CD133 aptamers
title Targeting lung cancer initiating cells by all-trans retinoic acid-loaded lipid-PLGA nanoparticles with CD133 aptamers
title_full Targeting lung cancer initiating cells by all-trans retinoic acid-loaded lipid-PLGA nanoparticles with CD133 aptamers
title_fullStr Targeting lung cancer initiating cells by all-trans retinoic acid-loaded lipid-PLGA nanoparticles with CD133 aptamers
title_full_unstemmed Targeting lung cancer initiating cells by all-trans retinoic acid-loaded lipid-PLGA nanoparticles with CD133 aptamers
title_short Targeting lung cancer initiating cells by all-trans retinoic acid-loaded lipid-PLGA nanoparticles with CD133 aptamers
title_sort targeting lung cancer initiating cells by all-trans retinoic acid-loaded lipid-plga nanoparticles with cd133 aptamers
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257334/
https://www.ncbi.nlm.nih.gov/pubmed/30542415
http://dx.doi.org/10.3892/etm.2018.6762
work_keys_str_mv AT zhangyu targetinglungcancerinitiatingcellsbyalltransretinoicacidloadedlipidplgananoparticleswithcd133aptamers
AT zhaojuan targetinglungcancerinitiatingcellsbyalltransretinoicacidloadedlipidplgananoparticleswithcd133aptamers
AT sunjing targetinglungcancerinitiatingcellsbyalltransretinoicacidloadedlipidplgananoparticleswithcd133aptamers
AT huanglu targetinglungcancerinitiatingcellsbyalltransretinoicacidloadedlipidplgananoparticleswithcd133aptamers
AT liqingfeng targetinglungcancerinitiatingcellsbyalltransretinoicacidloadedlipidplgananoparticleswithcd133aptamers